Literature DB >> 10510420

Liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry enantiomeric separation of dl-threo-methylphenidate, (Ritalin) using a macrocyclic antibiotic as the chiral selector.

L Ramos1, R Bakhtiar, T Majumdar, M Hayes, F Tse.   

Abstract

Vancomycin, a macrocyclic antibiotic, is an amphoteric glycopeptide produced by Streptomyces orientalis which has proven to be a viable chiral selector for high performance liquid chromatograph (HPLC) (D. W. Armstrong, Y. Tang, S. Chen, Y. Zhou, C. Bagwill and J-R. Chen, Anal. Chem. (1994; 66: 1473). While it is related to other glycopeptide antibiotics, vancomycin has a number of unique structural features, including 18 stereogenic centers, five aromatic rings, and two side chains one of which is a carbohydrate dimer. Therefore, a vancomycin-based stationary phase appears to be multimodal in that it can be utilized in both normal-phase and reversed-phase liquid chromatography. Consequently, the enantiomeric separation may be operative via several mechanisms, including pi-pi complexation, dipole stacking, inclusion, hydrogen bonding, or combinations of these interactions. LC/MS/MS is a powerful tool for quantitative analysis when evaluated on the basis of speed, specificity, reliability and sensitivity. For these reasons, the present paper explored the feasibility of bonded macrocyclic glycopeptide phases for chiral LC/MS/MS quantitative analysis. Methylphenidate was used as a model compound. A rapid chiral bioanalytical method (<7.5 min) for the determination of the enantiomers of methylphenidate was developed. A lower limit of quantification (LLOQ) of 87 pg/mL was attained for the human plasma assay. This is to our knowledge the first example of enantioselective reversed-phase LC/MS/MS for methylphenidate. The chiral column was relatively cost effective and exhibited excellent performance with no separation deterioration observed after approximately 2500 injections. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510420     DOI: 10.1002/(SICI)1097-0231(19991030)13:20<2054::AID-RCM749>3.0.CO;2-5

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  5 in total

1.  Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.

Authors:  Kennerly S Patrick; Wendy Rodriguez
Journal:  Drug Metab Dispos       Date:  2019-04-26       Impact factor: 3.922

2.  Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-02-25       Impact factor: 3.205

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Kennerly S Patrick; Jennifer L Donovan; C Lindsay DeVane; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-19       Impact factor: 3.205

Review 5.  Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.

Authors:  Rafał R Jaeschke; Ewelina Sujkowska; Magdalena Sowa-Kućma
Journal:  Psychopharmacology (Berl)       Date:  2021-08-26       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.